Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2006-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aim of this study is to investigate the value of magnetic resonance imaging using Vasovist as a contrast agent for the detection of endoleaks.
The advantages of magnetic resonance imaging with respect to CTA are no use of ionizing radiation, use of less nephrotoxic contrast agents.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Computed tomography angiography
Computed tomography angiography
Magnetic resonance imaging
Magnetic resonance imaging after injection of Vasovist
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient has a stable or growing aneurysm according to diameters measured on CT angiography images
* No evidence of endoleak on recent CT angiography
Exclusion Criteria
* claustrophobia
* pacemaker
* other non-MRI compatible implants
* contraindication for use of contrast agent
* known allergy to drugs or contrast media
* MRI examination with the use of gadolinium within 24 hours of the blood-pool agent injection
* severe renal impairment = creatine \> 2 mg/dl (=176 mmol/l)
* patient clinically instable
* Participation in drug research within 30 days before and 1 day after MRI-examination with use of Vasovist.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
INDUSTRY
UMC Utrecht
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
UMC Utrecht
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mathias Prokop, MD PhD
Role: PRINCIPAL_INVESTIGATOR
UMC Utrecht
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UMC Utrecht
Utrecht, Utrecht, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UMC_06_112
Identifier Type: -
Identifier Source: org_study_id